| scholarly article | Q13442814 |
| P50 | author | Minho Shong | Q67522725 |
| P2093 | author name string | Dong Wook Kim | |
| Ki Cheol Park | |||
| Young Suk Jo | |||
| Gi Ryang Kweon | |||
| Hyo Kyun Chung | |||
| Jung Hwan Hwang | |||
| Su-Jae Lee | |||
| Hye Sook Jung | |||
| Jung Hun Song | |||
| Ki-Won Jo | |||
| Su Hyeon Park | |||
| So Young Rha | |||
| P2860 | cites work | The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells | Q24519206 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thyroid cancer | Q826522 |
| P304 | page(s) | 4070-4076 | |
| P577 | publication date | 2006-07-18 | |
| P1433 | published in | The Journal of Clinical Endocrinology and Metabolism | Q3186902 |
| P1476 | title | An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases | |
| P478 | volume | 91 |
| Q33397590 | A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer |
| Q33401396 | A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors |
| Q43830000 | A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer |
| Q34250125 | A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours |
| Q33408559 | A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). |
| Q35206630 | Activated RET and ROS: two new driver mutations in lung adenocarcinoma |
| Q28247449 | Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations |
| Q38210345 | Advances in managing hepatocellular carcinoma |
| Q33932531 | An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer |
| Q37830361 | Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy |
| Q37875792 | Antiangiogenic treatments and mechanisms of action in renal cell carcinoma |
| Q43272877 | Biochemical and pathological response of prostate cancer in a patient with metastatic renal cell carcinoma on sunitinib treatment |
| Q37461714 | Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker |
| Q37098098 | Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib |
| Q38167995 | Central role of RET in thyroid cancer |
| Q60302337 | Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors |
| Q35001643 | Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure |
| Q35599819 | Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors. |
| Q37598938 | Clinicopathologic and molecular disease prognostication for papillary thyroid cancer. |
| Q28533671 | Combinatorial clustering of residue position subsets predicts inhibitor affinity across the human kinome |
| Q38091669 | Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis |
| Q33648995 | Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure |
| Q35895558 | Correlation of KIT and PDGFRA mutational status with clinical benefit in patients with gastrointestinal stromal tumor treated with sunitinib in a worldwide treatment-use trial |
| Q37578218 | Development of sunitinib in hepatocellular carcinoma: rationale, early clinical experience, and correlative studies |
| Q35864072 | Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease |
| Q37988591 | Dose optimization of tyrosine kinase inhibitors to improve outcomes in GIST. |
| Q38715683 | Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells |
| Q36132331 | Drosophila Cancer Models Identify Functional Differences between Ret Fusions |
| Q35829916 | Dual inhibiting EGFR and VEGF pathways versus EGFR-TKIs alone in the treatment of advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials |
| Q37357314 | Early development of sunitinib in hepatocellular carcinoma |
| Q43285136 | Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases |
| Q42140014 | Exploring the role of anti-angiogenic therapies in prostate cancer: results from the phase 3 trial of sunitinib |
| Q33400952 | First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study |
| Q37176371 | Gastrointestinal stromal tumors: key to diagnosis and choice of therapy |
| Q33723668 | Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis |
| Q39065451 | How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinoma |
| Q37902072 | How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer |
| Q36811817 | IGF-1 receptor is down-regulated by sunitinib induces MDM2-dependent ubiquitination |
| Q45943755 | Identification of potential tissue-specific cancer biomarkers and development of cancer versus normal genomic classifiers. |
| Q37778380 | Implications of mutational analysis for the management of patients with gastrointestinal stromal tumors and the application of targeted therapies |
| Q39939961 | Indomethacin inhibits cell growth of medullary thyroid carcinoma by reducing cell cycle progression into S phase |
| Q39315979 | Innovative in vitro chemo-hormonal drug therapy for refractory thyroid carcinomas. |
| Q33920800 | Investigational agents in development for the treatment of ovarian cancer |
| Q39563373 | Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma. |
| Q39567791 | Macrophage infiltration and its prognostic relevance in clear cell renal cell carcinoma. |
| Q55059234 | Mechanical induction of the tumorigenic β-catenin pathway by tumour growth pressure. |
| Q35184195 | Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinib |
| Q33557376 | Medullary thyroid carcinoma: targeted therapies and future directions |
| Q26774734 | Molecular Targeted Therapies of Aggressive Thyroid Cancer |
| Q37035285 | Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis |
| Q36157896 | Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. |
| Q83328373 | Multi-targeted approach in the treatment of thyroid cancer |
| Q38389986 | Multi-targeted tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: an era of individualized therapy |
| Q91599204 | New Treatment Options for Metastatic Thyroid Cancer |
| Q48986806 | New approaches for breast cancer: should Ret kinase be considered as a novel therapeutic target? |
| Q37238757 | New developments in the diagnosis and treatment of thyroid cancer |
| Q46017450 | New paradigms in gastrointestinal stromal tumour management. |
| Q36904500 | New perspectives on the treatment of differentiated thyroid cancer |
| Q42734670 | New targeted molecular therapies for dedifferentiated thyroid cancer |
| Q36724334 | New therapeutic approaches for metastatic thyroid carcinoma |
| Q35381593 | New therapies for dedifferentiated papillary thyroid cancer |
| Q34544846 | Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial |
| Q37872269 | Novel molecular targeted therapies for refractory thyroid cancer |
| Q89703945 | Novel treatments for anaplastic thyroid carcinoma |
| Q41607670 | Oncogenes, mitochondrial metabolism, and quality control in differentiated thyroid cancer. |
| Q37730394 | Optimal use of targeted agents for advanced gastrointestinal stromal tumours |
| Q37366059 | PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST |
| Q37130616 | Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib |
| Q37801868 | Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature |
| Q89737237 | Peptides containing the MXXCW motif inhibit oncogenic RET kinase activity with a novel mechanism of action |
| Q40922523 | Personalization of targeted therapy in advanced thyroid cancer |
| Q36308998 | Pharmacodynamic analysis of tumour perfusion assessed by 15O-water-PET imaging during treatment with sunitinib malate in patients with advanced malignancies |
| Q38099390 | Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors |
| Q43271774 | Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function |
| Q37258222 | Pharmacological control of receptor of advanced glycation end-products and its biological effects in psoriasis |
| Q43281012 | Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate |
| Q37424049 | Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer |
| Q80376810 | Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition |
| Q54527635 | Preliminary evaluation of serial (18) FDG-PET/CT to assess response to toceranib phosphate therapy in canine cancer. |
| Q27851455 | Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor |
| Q40221010 | RET and neuroendocrine tumors |
| Q36530631 | RET expression and detection of KIF5B/RET gene rearrangements in Japanese lung cancer |
| Q26740953 | Receptor tyrosine kinase (c-Kit) inhibitors: a potential therapeutic target in cancer cells |
| Q28388815 | Reconstruction of Tissue-Specific Metabolic Networks Using CORDA |
| Q51346796 | Reproductive toxicity assessment of sunitinib, a multitargeted receptor tyrosine kinase inhibitor, in male and female rats. |
| Q37413081 | Ret function in muscle stem cells points to tyrosine kinase inhibitor therapy for facioscapulohumeral muscular dystrophy. |
| Q37985518 | Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch |
| Q39025184 | Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor |
| Q46957688 | Sunitinib |
| Q33409913 | Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study |
| Q44282851 | Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma |
| Q37705402 | Sunitinib for the management of advanced renal cell carcinoma |
| Q38966228 | Sunitinib for the treatment of thyroid cancer |
| Q33996608 | Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study |
| Q35114038 | Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study |
| Q36197026 | Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial |
| Q54563946 | Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function. |
| Q39889569 | Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase |
| Q37686162 | Targeted molecular therapies in thyroid carcinoma |
| Q37860132 | Targeted therapies for thyroid tumors. |
| Q37629866 | Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management |
| Q35147151 | Targeted treatment of differentiated and medullary thyroid cancer |
| Q36356699 | Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry |
| Q37809678 | The Evolving Role of Histology in the Management of Advanced Non–Small-Cell Lung Cancer |
| Q27851744 | The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study |
| Q38144166 | The potential of sunitinib as a therapy in ovarian cancer |
| Q36180128 | The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells |
| Q48051735 | The structure of clinical translation: efficiency, information, and ethics |
| Q26796404 | The treatment landscape in thyroid cancer: a focus on cabozantinib |
| Q38208316 | Thyroid Cancer: Role of RET and Beyond |
| Q33760910 | Thyroid cancer: current molecular perspectives |
| Q37147768 | Thyroid carcinoma: molecular pathways and therapeutic targets |
| Q38579925 | Treatment of advanced thyroid cancer: role of molecularly targeted therapies |
| Q37686529 | Tyrosine kinase inhibitors to treat liver cancer |
| Q49569472 | Upregulation of RSPO2-GPR48/LGR4 signaling in papillary thyroid carcinoma contributes to tumor progression. |
| Q54548367 | [Current status and future direction of multi-targeted drugs in the era of personalized therapy--overview of advances in multi-targeted therapy in non-small cell lung cancer]. |
| Q45921946 | [The mitogen-activated protein kinase (MAPK) signaling pathway in papillary thyroid cancer. From the molecular bases to clinical practice]. |
Search more.